Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.
暂无分享,去创建一个
J. Bourhis | H. Dombret | S. Chevret | C. Preudhomme | P. Fenaux | C. Gardin | X. Thomas | O. Reman | P. Rousselot | C. Terré | E. Raffoux | N. Contentin | C. Pautas | D. Bordessoule | M. Michallet | S. Corm | P. Turlure | T. de Revel | S. Castaigne | F. Merabet
[1] M. Tallman,et al. A randomized trial of anthracycline dose intensification during induction of younger patients with acute myeloid leukemia: Results of Eastern Cooperative Oncology Group study E1900. , 2009, Journal of Clinical Oncology.
[2] C. Strahlendorf,et al. Providing research results to participants: attitudes and needs of adolescents and parents of children with cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] T. Naoe,et al. Updated Results of JALSG AML201 Study Comparing Intensified Daunorubicin with Idarubicin in Patients with De Novo Acute Myeloid Leukemia: Effect of Hematopoietic Stem Cell Transplantation. , 2008 .
[4] M. Caligiuri,et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] S. Feig,et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. , 2008, Blood.
[6] W. Hofmann,et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. , 2006, Blood.
[7] H. Dombret,et al. Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. , 2004, Blood.
[8] D. Neuberg,et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. , 2004, Blood.
[9] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[11] E. Estey,et al. A pilot study of interleukin‐2 for adult patients with acute myelogenous leukemia in first complete remission , 1999, Cancer.
[12] T. H. A. C. O. G. Roup. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia , 1998 .
[13] M. Grever,et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. , 1996, Blood.
[14] P. Berthaud,et al. Treatment of acute myelogenous leukaemia in patients aged 50–65: idarubicin is more effective than zorubicin for remission induction and prolonged disease‐free survival can be obtained using a unique consolidation course , 1996, British journal of haematology.
[15] J. Reiffers,et al. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. , 1996, Leukemia.
[16] O. Garson,et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. , 1996, Blood.
[17] L. Bergmann,et al. Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia. , 1995, Leukemia & lymphoma.
[18] R. Foà,et al. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. , 1994, Blood.
[19] R. Foà,et al. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival. , 1994, Leukemia.
[20] A. Bartolucci,et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] P. Ritch,et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. , 1992, Blood.
[22] F. Mandelli,et al. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia , 1991 .
[23] Janice Gabrilove,et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia , 1991 .
[24] E. Archimbaud,et al. Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance , 1991, British journal of haematology.
[25] F. Mandelli,et al. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA. , 1991, European journal of cancer.
[26] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .
[27] J. Peto,et al. Asymptotically Efficient Rank Invariant Test Procedures , 1972 .
[28] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[29] D.,et al. Regression Models and Life-Tables , 2022 .